Another study showed that different types of ceramides contribute differently to the risk of heart failure, higher plasma Cer-16 levels were associated with an increased risk of heart failure, while Cer-22 levels were associated with a reduced risk of heart failure (Lemaitre et al., 2019). This evidence concerns the gene CBLN1 and heart failure.